以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 近日，《自然》（Nature）旗下期刊Nature Reviews Endocrinology发布了一篇重磅综述，深入解析了影响体重反弹的多种潜在生物学机制。 这篇综述聚焦于那些通过调整生活方式成功减重后又出现体重反弹的人群，并探讨了多种预防体重回升的有效策略。文章指出，虽然通过改善 饮食结构或增加运动量等方式能够实现体重下降，但减重后体重反弹依然是长期管理肥胖的最大难题之一。 一项系统性回顾和meta分析（整合多项观察性研究数据）显示，依靠生活方式干预平均减重约14公斤的受试者中，约有75%的人会在5年左右 出现体重回升。 综述还强调，体重反弹并非仅限于生活方式干预人群，接受减肥手术或药物治疗后停药的人也常面临体重反弹的困扰。更有意思的是，减重后 体重反弹的情况在不同个体间差异巨大：有些人可以多年维持减重成果，而另一些人则在几个月内就恢复到原来的体重。深入 ...

整理 | GLP1减重宝典内容团队 中国目前是全球肥胖和超重人数最多的国家。根据2021年发表在《柳叶刀-糖尿病与内分泌学》上的研究数据，中国超过一半的成年人 口超重或肥胖，其中16.4%为肥胖，34.3%为超重，总人数高达约5.32亿，肥胖人数接近1亿。另一项2020年的研究预测，到2030年，中 国成年超重人数将达到5.4亿，肥胖人数将增至1.5亿，与2000年相比分别增长了2.8倍和7.5倍。 预计到2035年，全球约有四分之一的人口将被归为肥胖人群，而这一比例在2020年仅为14%。肥胖问题不仅影响个人的身心健康，还 对全球经济造成深远影响。据估计，这种影响相当于美国国内生产总值的3.6%，生产力损失带来的间接成本可能高达1.24万亿美元。 司美格鲁肽等GLP-1类药物的出现，彻底改变了减肥市场。然而，在司美格鲁肽热销的同时，也有大批的人在使用一段时间后放弃继续 用药。 点击关注，追踪最新GLP-1资讯 ▍有多少人停药？ 美国克利夫兰医学中心的研究者在《Obesity》期刊上发表的调查报告显示，司美格鲁肽在减肥药物中的依从性最高，这表明其副作用 相对较小。研究包括了司美格鲁肽、利拉鲁肽、芬特明-托吡酯 ...

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 近日，《自然》（Nature）旗下期刊Nature Reviews Endocrinology发布了一篇重磅综述，深入解析了影响体重反弹的多种潜在生物学机制。 这篇综述聚焦于那些通过调整生活方式成功减重后又出现体重反弹的人群，并探讨了多种预防体重回升的有效策略。文章指出，虽然通过改善 饮食结构或增加运动量等方式能够实现体重下降，但减重后体重反弹依然是长期管理肥胖的最大难题之一。 一项系统性回顾和meta分析（整合多项观察性研究数据）显示，依靠生活方式干预平均减重约14公斤的受试者中，约有75%的人会在5年左右 出现体重回升。 综述还强调，体重反弹并非仅限于生活方式干预人群，接受减肥手术或药物治疗后停药的人也常面临体重反弹的困扰。更有意思的是，减重后 体重反弹的情况在不同个体间差异巨大：有些人可以多年维持减重成果，而另一些人则在几个月内就恢复到原来的体重。深入 ...

Core Viewpoint - Obesity is a health condition associated with excess fat accumulation, leading to various complications and comorbidities. GLP-1 receptor agonists have been approved for treating obesity and type 2 diabetes, demonstrating effectiveness in appetite reduction and food intake decrease [2][3]. Group 1: Efficacy of GLP-1 Receptor Agonists - GLP-1 receptor agonists like semaglutide and tirzepatide have shown weight loss of 15%-20% compared to placebo over 68 to 72 weeks [3]. - Despite their effectiveness, about half of the patients discontinue treatment within the first year due to gastrointestinal side effects and high costs [3]. - Weight regain is common after stopping GLP-1 receptor agonists, emphasizing the need for continued use for sustained benefits [5][6]. Group 2: Weight Maintenance Challenges - A clinical trial indicated that participants who switched from semaglutide to placebo regained an average of 6.9% of their body weight, while those who continued treatment lost an additional 7.9% [6]. - After one year of stopping semaglutide, 18% of patients regained their lost weight, and 26% regained more than 25% of their weight [6]. Group 3: Treatment Duration and Guidelines - Patients should not stop medication before it takes effect and should continue for at least 12 weeks to see significant results. If effective, continuation for 9 months to 1 year is recommended [7]. - After three months of semaglutide use, patients typically experience a weight loss of 5.9%, increasing to 10.9% after six months [7]. Group 4: Strategies for Weight Management Post-Treatment - To prevent weight regain after stopping medication, patients should monitor appetite and weight closely, maintaining healthy eating habits and regular exercise [14]. - Dietary changes, such as reducing high-calorie foods and increasing protein and fiber intake, are crucial for weight maintenance [15]. - Incorporating strength training alongside aerobic exercise can enhance metabolic rate and support long-term weight loss [17]. Group 5: Importance of Sleep - Insufficient sleep can disrupt metabolic regulation, increasing hunger hormone levels and decreasing satiety hormone levels, leading to increased calorie intake [18]. - Adults are recommended to aim for 7-9 hours of sleep per night for optimal health and weight management [18].

Core Insights - The article emphasizes that weight loss is not merely about the numbers on a scale but involves significant changes in the underlying fat tissue, which can reverse aging processes in metabolic cells [7][9][10]. Group 1: Research Findings - A study published in July 2025 in *Nature* revealed that obesity accelerates the aging of metabolic and vascular cells within fat tissue, but weight loss can significantly reverse this premature aging phenomenon [7]. - The research highlights that while weight loss reduces inflammation, the memory of immune responses remains, posing a risk for potential weight regain [10][12]. - The study focused on subcutaneous abdominal fat, which is linked to central obesity and metabolic disorders like type 2 diabetes and hyperlipidemia, suggesting that understanding its dynamic changes is crucial for unlocking the health benefits of weight loss [8]. Group 2: Mechanisms of Weight Loss - Weight loss not only leads to a decrease in body weight but also transforms the structure and function of fat tissue towards a healthier state, driven by complex immune regulatory mechanisms [10][15]. - Despite improvements in local inflammation and reductions in inflammatory markers, some macrophages remain in a pre-activated state, which could trigger inflammation again upon encountering new stimuli, potentially leading to weight regain [10][15]. Group 3: Long-term Effects of Obesity - Research indicates that even after successful weight loss, changes at the cellular level persist, with fat cells retaining characteristics from the obese state, which may lead to faster fat accumulation upon re-exposure to high-fat diets [15][19]. - Animal studies corroborate these findings, showing that fat tissue in obese mice retains a form of epigenetic memory that influences their metabolic responses even after weight loss [19]. Group 4: Implications for Weight Management - The persistent "obesity memory" in fat tissue and immune cells suggests that weight management strategies must consider these long-term changes to prevent weight regain and associated metabolic diseases [19]. - The article underscores the importance of developing comprehensive weight management approaches that address both the physiological and psychological aspects of obesity [19].

Core Insights - The article emphasizes that weight loss is not merely about the numbers on the scale but involves significant changes in the underlying fat tissue, which can reverse aging processes in metabolic cells [7][9][10] - It highlights the persistent "memory" of inflammation in immune cells and fat tissue, which can lead to weight regain after initial weight loss [10][15][19] Group 1: Research Findings - A study published in July 2025 in *Nature* revealed that obesity accelerates the aging of metabolic and vascular cells in fat tissue, while weight loss can significantly reverse this premature aging [7] - The research indicates that while weight loss reduces inflammation, the immune system retains a "memory" of the previous obese state, which may contribute to weight regain [10][12] - The study focused on subcutaneous abdominal fat, linking it to metabolic disorders such as type 2 diabetes and hyperlipidemia, suggesting that understanding its dynamics is key to unlocking the health benefits of weight loss [8] Group 2: Mechanisms of Weight Loss - Weight loss not only reduces body weight but also transforms the structure and function of fat tissue towards a healthier state, involving complex immune regulatory mechanisms [10][15] - Despite improvements in local inflammation and reduced expression of inflammatory factors, some macrophages remain in a pre-activated state, posing a risk for future inflammation and weight regain [10][12] - Research shows that even two years after successful weight loss, fat cells retain changes from the obese state, leading to increased absorption of sugars and fats, which can accelerate fat accumulation upon re-exposure to high-calorie diets [15][19] Group 3: Experimental Evidence - Animal studies using C57BL/6J mice demonstrated that after weight loss, the fat tissue still exhibited increased macrophage presence and persistent gene expression changes associated with obesity [17][19] - The findings indicate that these "obesity memories" in fat cells can lead to abnormal responses to metabolic stimuli, contributing to the risk of weight regain and the recurrence of obesity-related metabolic diseases [19]

Core Viewpoint - Obesity is a health condition associated with excess fat accumulation, leading to various complications and comorbidities. GLP-1 receptor agonists have been approved for treating obesity and type 2 diabetes, demonstrating effectiveness in appetite reduction and food intake decrease [2][3]. Group 1: Efficacy of GLP-1 Receptor Agonists - GLP-1 receptor agonists like semaglutide and tirzepatide have shown weight loss of 15%-20% compared to placebo after 68 and 72 weeks of treatment, respectively [3]. - Despite their effectiveness, about half of the patients discontinue treatment within the first year due to gastrointestinal side effects and high costs [3]. - A clinical trial indicated that participants who continued semaglutide lost an average of 17.3% of their weight over 68 weeks, while those who switched to placebo regained approximately 6.9% of their weight [6]. Group 2: Challenges in Weight Maintenance - One of the biggest challenges in weight loss is maintaining the results, as many individuals experience weight regain after stopping treatment. Studies show that discontinuation of GLP-1 receptor agonists often leads to weight gain [5]. - After stopping semaglutide, 18% of patients regained their previous weight, and 26% regained more than 25% of their lost weight within a year [6]. Group 3: Treatment Duration and Strategies - It is recommended to continue treatment for at least 12 weeks before assessing effectiveness, with a suggested duration of 9 months to 1 year for consolidation therapy if significant weight loss is observed [7]. - Initial weeks of semaglutide treatment may lead to increased satiety and reduced food intake, although mild side effects like nausea may occur [10][11]. Group 4: Discontinuation and Monitoring - Gradual dose reduction is advised when discontinuing semaglutide to mitigate increased hunger sensations, especially for non-diabetic patients [12]. - Patients are encouraged to monitor their appetite and weight closely after stopping medication, and to maintain healthy eating habits and regular exercise to prevent weight rebound [14]. Group 5: Strategies to Prevent Weight Regain - Key strategies to prevent weight regain include altering dietary habits by reducing high-calorie foods and increasing protein and fiber intake to enhance metabolism [15]. - Incorporating strength training alongside aerobic exercises can help maintain weight loss by increasing muscle mass and metabolic rate [17]. - Adequate sleep is crucial for metabolic regulation, with 7-9 hours of sleep recommended for optimal health [18].

Core Viewpoint - Obesity is a health condition associated with excess fat accumulation, leading to various complications and comorbidities. GLP-1 receptor agonists have been developed and approved for obesity treatment, demonstrating effectiveness in appetite reduction and weight loss [1][2][4]. Summary by Sections Treatment Efficacy - GLP-1 receptor agonists, such as semaglutide and tirzepatide, have shown weight loss of 15%-20% after 68 to 72 weeks compared to placebo [2]. - A clinical trial indicated that participants lost an average of 10.6% of their body weight during 20 weeks of semaglutide treatment, with those continuing the drug losing an additional 7.9% over 48 weeks [5]. Challenges in Weight Maintenance - One of the biggest challenges in weight loss is maintaining the results, as many individuals experience weight regain after stopping treatment. Studies show that stopping GLP-1 receptor agonists can lead to significant weight gain [4][5]. - After one year of stopping semaglutide, approximately two-thirds of the weight lost can be regained [5]. Medication Management - It is recommended to continue GLP-1 receptor agonist treatment for at least 12 weeks to see significant effects, with a suggested continuation of 9 months to 1 year for consolidation [6]. - Users may experience increased satiety and reduced food intake initially, with weight loss typically ranging from 0.5 to 2 pounds per week [9]. Discontinuation Strategies - Gradual dose reduction is advised when stopping the medication to mitigate increased hunger, with specific recommendations for both non-diabetic and diabetic patients [10][12]. - Maintaining healthy eating habits and regular exercise is crucial post-discontinuation to prevent weight rebound [12]. Dietary and Lifestyle Recommendations - Key strategies to prevent weight regain include altering dietary habits by reducing high-calorie foods and increasing protein and fiber intake [13]. - Incorporating strength training and ensuring adequate sleep (7-9 hours per night) are also essential for maintaining weight loss and improving metabolic health [15].

Core Viewpoint - The article discusses the challenges of weight management and the phenomenon of weight regain after dieting, emphasizing the need for innovative solutions in the weight loss industry to combat this issue [1][2][6]. Group 1: Weight Management Initiatives - The National Health Commission of China has launched a three-year "Weight Management Year" initiative aimed at reducing weight and controlling chronic diseases [1]. - The concept of "metabolic memory" explains why individuals often regain weight after losing it, as the body tends to remember previous weight levels [2][6]. Group 2: Current Market Dynamics - The weight loss market is seeing significant sales, with drugs like semaglutide generating annual revenues of $28.3 billion [3]. - Major pharmaceutical companies, including Novo Nordisk and Eli Lilly, are focusing on developing new mechanisms and improving existing products to address muscle loss and weight regain during weight loss [2][10]. Group 3: Challenges in Weight Loss - Many weight loss methods lead to muscle loss, which can decrease the basal metabolic rate and exacerbate weight regain after stopping treatment [10]. - A study published in the Journal of the American Medical Association indicated that participants who stopped taking the weight loss drug tirzepatide regained an average of 14% of their lost weight within a year [8]. Group 4: Innovative Solutions and Research - Companies are exploring new drug targets and combination therapies to enhance weight loss while preserving muscle mass [10][11]. - The UK company NodThera is investigating an anti-inflammatory approach to weight loss, which has attracted interest from major players like Novo Nordisk [11]. Group 5: Long-term Weight Management Strategies - Experts recommend sustainable lifestyle changes, including balanced diets and regular exercise, as more effective long-term strategies for weight management compared to quick fixes [12][13]. - A comprehensive approach to weight management may involve a treatment cycle lasting over 20 months, focusing on identifying causes of obesity and designing personalized weight loss strategies [12].